NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Analysis

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CRBP

$4.29

−$0.13 (−3.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRBP with… →

CRBP Key Statistics

As of Oct 21, 2026
Trading
Open
$4.45
Previous Close
$4.42
Day's Range
4.28–4.57
52-Week Range
4.22–19.55
Volume
625.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.63
Valuation
Market Cap
$82.88M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.11
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$78.54M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.34M
1-Year Return
−77.87%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
839.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CRBP closed at $4.29, −77.87% over 1 year.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a market capitalization of $82.88M.

In fiscal 2025, CRBP reported revenue of $0.00.

CRBP Stock Return by Calendar Year

Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10-year return: what $10,000 became

1 year
$10,000 $2,213
−77.87%
5 years
$10,000 $1,387
−86.13%
10 years
$10,000 $160
−98.40%

If you had invested $10,000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, at the close on October 21, 2016, it would have been worth $160 at the close on October 21, 2026: −98.40% in total, −33.88% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−47.36%
2025−31.02%
2024+95.36%
2023+81.38%
2022−81.98%
2021−50.72%
2020−77.11%
2019−6.51%
2018−17.75%
2017−15.98%
2016 (partial year)+182.61%

As of October 21, 2026.

CRBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$78.54M—
2024$0.00−$40.21M—
2023$0.00−$44.60M—
2022$0.00−$42.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$85.31M−$78.54M—
2024$0.00—−$48.72M−$40.21M—
2023$0.00—−$45.08M−$44.60M—
2022$0.00—−$34.84M−$42.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $82.88M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 36.

The most recent close on file for CRBP is $4.29, dated October 21, 2026. That is −$0.13 (−3.05%) against the previous close. Over the past 52 weeks the price has ranged from $4.22 to $19.55. The latest close sits 1.54% above that 52-week low.

Financial Health

In fiscal 2025, Corbus Pharmaceuticals Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $78.54M. Earnings per share on a trailing basis come to −6.11.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.63. Daily returns over the trailing 10 years annualize to a volatility of 128.26%. The trailing one-year total return is −77.87%. Measured over 10 years, that is −33.88% a year compounded.

Growth & Income

No dividend is on file for CRBP.

So far in 2026 the total return is −47.36%. The strongest complete calendar year on file is 2024 at +95.36%; the weakest is 2022 at −81.98%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Corbus Pharmaceuticals Holdings, Inc. (CRBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Corbus Pharmaceuticals Holdings, Inc. CRBP $82.88M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Corbus Pharmaceuticals Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Visit website →